Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.

Abstract: Methods and systems are provided for decoding movement intentions using functional ultrasound (fUS) imaging of the brain. In one example, decoding movement intentions include determining a memory phase of a cognitive state of the brain, the memory phase between a gaze fixation phase and movement execution phase, and determining one or more movement intentions including one or more of intended effector (e.g., hand, eye) and intended direction (e.g., right, left) according to a machine learning algorithm trained to classify one or more movement intentions simultaneously.

Abstract: The present invention relates to the treatment of HCMV relates diseases. The inventors conducted a study to find an essential domain of pUL56 for its interaction with pUL89 which is important in the effect of the CMV. Sequences alignments allowed them to predict one sequence in C-terminal of pUL56 potentially necessary for interaction with pUL89. BAC mutagenesis and AlphaLISA technologies using purified proteins allowed to validate that the short sequence 671WMVVKYMGFF680 (SEQ ID NO: 1) in C-terminal of pUL56 is involved in interaction with pUL89. Knowing this important information, antibodies directed against this sequence or peptides derived from this sequence could be useful to invalidate the interaction of pUL56 to pUL89 and thus to treat HCMV related diseases.

Abstract: This method for acquiring a spatial map of auditory perception of a subject comprises a plurality of successive test sequences, each test sequence comprising steps of: a) calibration (1002) of the subject's position, by displaying instructions to the subject, using a head-mounted visual display system worn by the subject, in order to acquire a reference position of the subject, the subject's position being measured using a video motion capture system by measuring the spatial coordinates of a first optical marker worn by the subject, b) choosing (1004) spatial coordinates of a target location of a sound source, said target cation being located around the subject, c) emitting (1006) a predefined sound, using a sound source placed at said target location, d) in response to acquisition instructions generated by the subject using an acquisition interface, acquiring (1008) an estimated location of said sound source, by using the video motion capture system to measure the spatial coordinates of a second optical mark

Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

Abstract: A regenerative material in the connective tissues (such as bone, dentin or pulp) regeneration field. More precisely, a connective tissue regenerative material, preferably a bone, dentin or pulp regenerative material, including: a porous polymer matrix having interconnected pores; and non-hydrated calcium silicate particles; wherein: the polymer matrix is anhydrous; the non-hydrated calcium silicate particles have a d50granulometry, preferably ranging from 0.05 ?m to less than the average diameter size of the pores of the matrix; and the non-hydrated calcium silicate particles being coated on the inside walls of the pores of the matrix. Also, a method for preparing the connective tissue regenerative material and uses of the regenerative materials, such as in the dental field; especially, for providing regenerative materials with improved biomechanical and osteoinductive properties (i.e.

Abstract: A vibrotactile stimulation device intended to be applied against a body environment (MC) to be stimulated and having a vibrating effector suitable for applying, to the environment, pulses of mechanical vibrational energy, and a controller controlling the effector according to stimulation rules. The device further includes vibration detector suitable for being exposed to the body environment in order to receive a part of the vibrational energy transmitted to the environment during the application of the pulses of vibrational energy, and determine a transmission characteristic of the vibrational energy between the effector and the environment to be stimulated, the vibration detector being linked to the controller. An application to improving the efficacy of body stimulation in combating sleep apnea is also disclosed.

Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.

Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to in vitro non invasive methods and kits for determining the quality of an embryo by determining the level of the cell free nucleic acids and/or determining the presence and/or expression level of at least one specific nucleic acid sequence in the nucleic acid extraction.

Abstract: The present invention generally relates to an immunogenic construct, useful for redirecting an EBV-existing immune response towards an undesired target cell and/or microorganism, to methods for preparing said conjugate, to a pharmaceutical applications comprising said conjugate, and to medical applications thereof.

Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.

Abstract: A method for the generation of a consciousness indicator for a non-communicating subject, including generating a sensory stimulation involving at least one of the five senses, the sensory stimulation having multiple consecutive stimuli including at least a first stimulus and a second stimulus relating to the same sense and different from one another, measuring an electrocardiographic signal of the subject during the generation of the sensory stimulation, extracting at least one EKG feature from the electrocardiographic signal associated to cognitive processes and generating a consciousness indicator using the EKG features as input of a classifier.

Abstract: The present invention improves the quality of the magnitude and phase images produced in medical imaging, in particular in the case of multi-antenna MRI. The invention proposes to generate (28) such an image (I) by summing the complex image data (pj,{tilde over (p)}j) obtained from different antennas by weighting these data using only the diagonal elements (Rj,j) of an antenna noise covariance matrix or its inverse or pseudo-inverse matrix (Rj,j?1). A reference antenna (Ref) may be determined (24), so as to be able to replace (26), in each of these datum, a phase component specific to the acquisition antenna by a reference phase component. The reference antenna is preferably a virtual antenna formed by linear combination of the antennas of the MRI system. If significant improvements are obtained in the phase image resulting from the summation, a very clear gain is also surprisingly obtained in the magnitude image.

Abstract: In order to obtain a predetermined ultrasonic wave field in a homogeneous internal part of a medium masked by an aberrating barrier, an ultrasonic lens is interposed between the emitting ultrasonic probe and the aberrating barrier. The ultrasonic lens is calculated by using a model of the medium comprising a mapping of ultrasonic wave propagation properties obtained from actual imaging of the medium such that when the ultrasound probe sends a predetermined ultrasonic wave, said predetermined wave generates the predetermined objective ultrasonic wave field in the medium.

Abstract: Disclosed are agents activating CD47 and their use in the treatment of inflammation, in particular non-resolving low grade inflammation, characterized by chronic MP infiltration, such as age-related macular degeneration. Also disclosed are pharmaceutical compositions, medicaments and kits including the agents.

Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth regardation disorders, such as achondroplasia.

Abstract: A therapy apparatus for treating tissue by the emission of focused ultrasound waves, including: a creation surface of a pressure field of focused ultrasound waves divided into at least N sectors having segments of asymmetrical concave curve (S1, S2, . . . ) with centres of curvature; centres of curvature (c1, c2, . . . ) asymmetrical to the extent where the centres of curvature are situated at different distances from the plane of symmetry (A1) or from the axis of symmetry (S) and/or at different depths taken according to the axis of symmetry; the individual axes (a1, a2, . . . ) intersecting between the focal zones (Zc1, Zc2, . . . ) and the creation surface (8) or beyond the focal zones such that the beams originating from the sectors intersect to create a focal coverage zone (Zr) which is off-axis relative to the plane of symmetry (A1) or to the axis of symmetry (S); the sectors of this creation surface (8) creating energy deposit zones with profiles corresponding to the focal coverage zones (Zr).

Abstract: System (1) for treatment by photodynamic therapy comprising an illuminating member (6) which comprises: —a core (35) carrying a light emitting surface (37), and —a hollow sheath (10) adapted to receive the core (35) with the light emitting surface (37) arranged within a balloon (11), the balloon (11) comprising a wall (12) which has an inner surface delimiting an internal space, and an outer surface, the wall (12) being flexible, wherein the internal space of the balloon (11) has a variable capacity, the wall (12) of the balloon (11) being elastically extendible and the balloon (11) presenting a plurality of inflated states in each of which the internal space is filled with a volume of light diffusing solution, and wherein the system further comprises a support provided with a transfer function relating the volume of light diffusing solution of each inflated state with at least one of a corresponding distribution of light power at the outer surface of the wall (12) of the balloon (11) and a corresponding time

Abstract: The present application describes and claims a novel method for identifying and stratifying the risk of developing a BK virus nephropathy (“Nx BK-v” below) in patients having undergone a kidney transplant. This method uses an index combining at least three bio-markers: i) the intensity of the anti-BK-v memory T lymphocyte response (memory T lymphocytes which are specific to v, hereinafter “LTm anti-BK-v”), ii) the number of occurrences of incompatibility in the HLA alleles of class I and class II between the donor and the recipient of the graft, taking into account iii) the viral charge of the BK-v virus in the whole blood of the patient. The present method allows a very precise evaluation of the risk of developing an Nx BK-v during the months following the test with the aim of optimising the immuno-suppressive treatment in order to better preserve the transplanted kidney.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cystic fibrosis. In particular, the present invention relates to a method of treating cystic fibrosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nucleic acid miR-9 inhibitor.